Johnson & Johnson (N:JNJ)

Oct 18, 2019 08:38 am ET
Johnson & Johnson Consumer Inc. To Voluntarily Recall A Single Lot Of Johnson's Baby Powder In The United States
NEW BRUNSWICK, N.J., Oct. 18, 2019 /PRNewswire/ -- Out of an abundance of caution, Johnson & Johnson Consumer Inc. (JJCI) announced that it is initiating a voluntary recall in the United States of a single lot of its Johnson's Baby Powder in response to a U.S. Food and Drug Administration (FDA) test indicating the presence of sub-trace levels of chrysotile asbestos contamination (no greater than 0.00002%) in samples from a single bottle purchased from an online retailer. Despite the low levels reported and in full cooperation and collaboration with the FDA, JJCI is initiating this volunt...
Oct 17, 2019 11:45 am ET
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2019
NEW BRUNSWICK, N.J., Oct. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2019 of $0.95 per share on the company's common stock. The dividend is payable on December 10, 2019 to shareholders of record at the close of business on November 26, 2019. The ex-dividend date is November 25, 2019....
Oct 15, 2019 06:43 am ET
Johnson & Johnson Reports 2019 Third-Quarter Results
NEW BRUNSWICK, N.J., Oct. 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2019. "Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharmaceuticals and Medical Devices, as well as continued optimization in our Consumer business," said Alex Gorsky, Chairman and Chief Executive Officer. "As we look ahead, we remain confident in the strength of our broad-based business model, which is fueled by our disciplined portfolio management, focus on transformational innovation and dedicated employees aro...
Oct 09, 2019 09:31 am ET
Thinking about trading options or stock in Apple, Citigroup, FedEx, Johnson & Johnson, or NVIDIA?
NEW YORK, Oct. 9, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, C, FDX, JNJ, and NVDA....
Oct 07, 2019 08:00 am ET
Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review
NEW BRUNSWICK, N.J., Oct. 7, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), the world's largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review (Impact Review), which demonstrates how a strategic Diversity & Inclusion (D&I) philosophy has been a key driver of innovation and impactful business outcomes since its founding more than 130 years ago. Through collaborative achievements and personal stories, the Impact Review explores how the collective wisdom and commitment to inclusion of the 135,000 Johnson & John...
Oct 04, 2019 07:30 am ET
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
NEW BRUNSWICK, N.J., Oct. 4, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and tuberculosis (TB) by 2030.  As one of the world's largest healthcare companies, Johnson & Johnson is deeply engaged in global health innovation, working closely with governments and strategic partners to improve the health and well-being of more people in more places around the world. ...
Oct 03, 2019 09:31 am ET
Thinking about trading options or stock in Apple, Facebook, Johnson & Johnson, Visa, or Walmart?
NEW YORK, Oct. 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, FB, JNJ, V, and WMT....
Oct 01, 2019 07:46 pm ET
Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial
NEW BRUNSWICK, N.J., Oct. 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no admission of liability and removes the Company from the federal trial scheduled to begin October 21, 2019. As part of the agreement, the Company will make a combined $10 million settlement payment to the counties....
Sep 30, 2019 11:21 am ET
California Jury Returns $40 Million Talc Verdict Against Johnson & Johnson
LOS ANGELES, Sept. 30, 2019 /PRNewswire/ -- A California woman suffering from mesothelioma has prevailed in the latest talc trial against Johnson & Johnson, following six days of jury deliberation that ended Friday when the jury awarded her $40 million in damages....
Sep 30, 2019 08:00 am ET
Johnson & Johnson Vision Care, Inc. Introduces ACUVUE™ RevitaLens Multi-Purpose Disinfecting Solution, the Brand's First Contact Lens Solution
JACKSONVILLE, Fla., Sept. 30, 2019 /PRNewswire/ -- Johnson & Johnson Vision† is excited to unveil the first-ever extension of the ACUVUE® brand name beyond contact lenses with today's launch of ACUVUE™ RevitaLens Multi-Purpose Disinfecting Solution (MPDS). ACUVUE™ RevitaLens MPDS delivers exceptional disinfection and all-day comfort for reusable contact lens wearers.1 Its innovative dual-disinfecting formula is gentle on the eyes but tough on harmful germs and bacteria,1 making it a convenient and effective contact lens solution that eye care professionals can recommend with confidence. ...
Sep 18, 2019 04:06 pm ET
Johnson & Johnson to Host Investor Conference Call on Third Quarter Results
NEW BRUNSWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15th to review third-quarter results.  Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call.  The question and answer portion of the call will also include the following executives: Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices; Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consu...
Sep 16, 2019 11:30 am ET
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
NEW YORK, Sept. 16, 2019 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q2 2019 S&P 500® stock buybacks, or share repurchases, were $164.5 billion. This was the second consecutive quarterly decline after four consecutive quarters of record buybacks. Q2 2019 buybacks were 20.1% lower than Q1 2019's $205.6 billion, 13.7% lower year-over-year from Q2 2018's $190.6 billion, and 26.2% lower than the Q4 2018 record expenditure of $223.0 billion.  ...
Sep 06, 2019 09:31 am ET
Thinking about trading options or stock in Apple, Goldman Sachs, Johnson & Johnson, Microsoft, or Tesla?
NEW YORK, Sept. 6, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, GS, JNJ, MSFT, and TSLA....
Aug 29, 2019 04:24 pm ET
Johnson & Johnson to Participate in the 2019 Morgan Stanley 17th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J., Aug. 29, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2019 Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th, at The Grand Hyatt Hotel in New York.  Peter F. Lebowitz, M.D., Ph.D. Global Therapeutic Area Head, Oncology and Scott White, Company Group Chairman North America Pharmaceuticals will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). ...
Aug 27, 2019 09:31 am ET
Thinking about trading options or stock in Apple, Salesforce, Facebook, Johnson & Johnson, or Tyson Foods?
NEW YORK, Aug. 27, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CRM, FB, JNJ, and TSN....
Aug 26, 2019 04:59 pm ET
Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma
NEW BRUNSWICK, N.J., Aug. 26, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies today announced they will appeal the $572 million civil judgment entered in Cleveland County District Court in the State of Oklahoma's lawsuit against opioid manufacturers. The Company is confident it has strong grounds to appeal this decision....
Aug 21, 2019 09:31 am ET
Thinking about trading options or stock in Walt Disney Co, Johnson & Johnson, Netflix, Target, or Walmart?
NEW YORK, Aug. 21, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIS, JNJ, NFLX, TGT, and WMT....
Aug 16, 2019 10:50 pm ET
JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (NYSE: JNJ).
Aug 12, 2019 09:31 am ET
Thinking about trading options or stock in AbbVie, Bristol-Myers Squibb, Goldman Sachs, Johnson & Johnson, or Micron Technology?
NEW YORK, Aug. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, BMY, GS, JNJ, and MU....
Aug 08, 2019 02:42 pm ET
Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference
NEW BRUNSWICK, N.J., Aug. 8, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, September 5th, at the InterContinental, Boston, MA.  Thibault Mongon, Executive Vice President, Worldwide Chairman Consumer will represent the Company in a session scheduled at 7:30 a.m. (Eastern Time). ...
Aug 08, 2019 02:32 pm ET
Johnson & Johnson to Participate in the Wells Fargo Securities 2019 Healthcare Conference
NEW BRUNSWICK, N.J., Aug. 8, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 14th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 5th, at The Westin Copley Place in Boston, MA.  Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 9:45 a.m. (Eastern Time).  ...
Aug 08, 2019 08:01 am ET
Yield Growth Corp Provides Mid-Year 2019 Corporate Update
via OTC PR WIRE -- The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce its second quarter investor highlights. Over the past several months, the company has undertaken several initiatives to increase its reach and...
Aug 02, 2019 10:50 pm ET
JOHNSON & JOHNSON INVESTIGATION UPDATE BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ
NEW ORLEANS, Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Johnson & Johnson ("J&J") (NYSE: JNJ).  ...
Jul 19, 2019 10:50 pm ET
JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (NYSE: JNJ).
Jul 16, 2019 06:40 am ET
Johnson & Johnson Reports 2019 Second-Quarter Results
NEW BRUNSWICK, N.J., July 16, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2019. "We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses," said Alex Gorsky, Chairman and Chief Executive Officer. "Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am pr...
Jul 15, 2019 10:58 am ET
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2019
NEW BRUNSWICK, N.J., July 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2019 of $0.95 per share on the company's common stock. The dividend is payable on September 10, 2019 to shareholders of record at the close of business on August 27, 2019. The ex-dividend date is August 26, 2019....
May 17, 2019 08:52 am ET
Johnson & Johnson to Participate in Bernstein's 35th Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J., May 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in Bernstein's 35th Annual Strategic Decisions Conference on Thursday, May 30, at the Grand Hyatt, New York.  Alex Gorsky, Chairman and Chief Executive Officer, will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time). ...
May 15, 2019 06:40 am ET
Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review
NEW BRUNSWICK, N.J., May 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a meeting today with industry analysts to review the strategy of its Janssen Pharmaceutical Companies to deliver above-market, compound annual growth through 2023. The company will also discuss its progress across its six therapeutic areas, pipeline developments and capital allocation framework. ...
Apr 25, 2019 10:40 am ET
Johnson & Johnson Announces Dividend Increase of 5.6%
NEW BRUNSWICK, N.J., April 25, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 5.6% increase in the quarterly dividend rate, from $0.90 per share to $0.95 per share.  The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, N.J....
Apr 24, 2019 06:44 pm ET
Johnson & Johnson to Host Pharmaceutical Business Review
NEW BRUNSWICK, N.J., April 24, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceutical businesses for the investment community beginning at 8:30 a.m. (Eastern Time) on Wednesday, May 15, 2019 at the Hyatt Regency Hotel in New Brunswick, New Jersey, and ending at approximately 2:30 p.m....
Apr 16, 2019 09:31 am ET
Thinking about buying stock in Advanced Disposal Services Inc., Bank of America Corp., Canopy Growth Corp., Fibrocell Science, or Johnson & Johnson?
NEW YORK, April 16, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADSW, BAC, CGC, FCSC, and JNJ....
Apr 16, 2019 06:40 am ET
Johnson & Johnson Reports 2019 First-Quarter Results:
NEW BRUNSWICK, N.J., April 16, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2019. "Our strong first-quarter results reflect continued underlying operational sales and adjusted EPS growth," said Alex Gorsky, Chairman and Chief Executive Officer. "At the same time, we remain focused on investing in innovative technologies and platforms that will make a meaningful difference in the lives of patients around the world. I am proud of our global colleagues' collective efforts to deliver on our long-term goals and our ability to create value for al...
Apr 15, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis Inc., BlackRock Inc., Canopy Growth Corp., Johnson & Johnson, or Wells Fargo & Co.?
NEW YORK, April 15, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BLK, CGC, JNJ, and WFC....
Apr 10, 2019 08:30 am ET
New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust, Comtech Telecommunications, and Odonate Therapeutics — Factors of Influenc
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Newmont Mining Corporation (NYSE:NEM), Johnson & Johnson (NYSE:JNJ), Portola...
Apr 01, 2019 04:30 pm ET
Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc.
NEW BRUNSWICK, N.J., April 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. With Auris Health's robotic platform technology, currently used in diagnostic and therapeutic procedures in the lung, Johnson & Johnson will advance its commitment to combatting lung cancer and expand its digital surgery portfolio across multipl...
Apr 01, 2019 04:30 pm ET
Johnson & Johnson Completes Divestiture of Advanced Sterilization Products (ASP) to Fortive Corporation
NEW BRUNSWICK, N.J., April 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, to Fortive Corporation (NYSE: FTV) for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds from Fortive Corporation and $0.1 billion of retained net receivables. ASP is a global leader in innovative infection prevention solutions with 2018 net revenue of approximately $800 million. ...
Mar 28, 2019 12:09 pm ET
Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in Canada
Baseball Superstar Bryce Harper Named Ambassador for New Contact Lenses that Seamlessly Adapt to Changing Light Conditions[1]...
Mar 27, 2019 04:49 pm ET
Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in the U.S.
JACKSONVILLE, Fla., March 27, 2019 /PRNewswire/ -- Johnson & Johnson Vision today announced the U.S. availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY. The first-of-its-kind2 photochromic contact lens was named one of TIME's 'Best Inventions of 2018.' The contact lenses seamlessly adapt to changing light, helping eyes recover from bright light up to five seconds faster, reducing halos and starbursts at night,• and delivering more effortless sight with less squinting, from dawn to dusk.1,3, ••  ...
Mar 25, 2019 12:09 pm ET
Settlement Reached Resolving Xarelto Multidistrict Litigation Claims
NEW ORLEANS, March 25, 2019 /PRNewswire/ -- The makers of the popular blood thinner Xarelto® have reached a $775 million settlement to resolve litigation filed by patients who suffered a bleeding injury after taking the prescription drug....
Mar 25, 2019 10:53 am ET
S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion
NEW YORK, March 25, 2019 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q4 2018 S&P 500® stock buybacks, or share repurchases, set a fourth consecutive record of $223.0 billion. This displaces the previous record of $203.8 billion, set during Q3 2018 and is a 62.8% increase from the $137.0 billion reported for Q4 2017. ...
Mar 19, 2019 10:53 am ET
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
NEW BRUNSWICK, N.J., March 19, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th, to review first-quarter results.  Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call.  The question and answer portion of the call will also include the following executives: Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices; Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consum...
Feb 28, 2019 10:55 am ET
Johnson & Johnson to Participate in Barclays Global Healthcare Conference
NEW BRUNSWICK, N.J., Feb. 28, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Thursday, Mar. 14, at the Loews Miami Beach Hotel, Miami, FL.  Tom Cavanaugh, President, Oncology and Catherine Owen, President, Immunology will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). ...
Feb 21, 2019 07:35 am ET
Research Report Identifies Johnson & Johnson, Schlumberger, Karyopharm Therapeutics, WYNDHAM DESTINATIONS, INC, ASGN, and Suburban Propane Partners with Renewed Outlook — Fundamental Analysis, Calcula
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Johnson & Johnson (NYSE:JNJ), Schlumberger Limited (NYSE:SLB), Karyopharm...
Feb 14, 2019 09:31 am ET
Johnson & Johnson to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
NEW BRUNSWICK, N.J., Feb. 14, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, Feb. 28th, at Lotte New York Palace, NY.  Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time). ...
Feb 13, 2019 08:00 am ET
Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.
NEW BRUNSWICK, N.J., Feb. 13, 2019 /PRNewswire/ -- Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therap...
Feb 05, 2019 03:36 pm ET
Johnson & Johnson to Participate in the 2019 CAGNY Conference
NEW BRUNSWICK, N.J., Feb. 5, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2019 CAGNY Conference on Tuesday, Feb. 19, at The Boca Raton Resort, Boca Raton, FL.  Alison Lewis, Global Chief Marketing Officer for Johnson & Johnson Consumer, Inc. will represent the Company in a session scheduled at 9:00 a.m. (Eastern Time). ...
Feb 01, 2019 10:50 pm ET
JOHNSON & JOHNSON INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Johnson & Johnson - JNJ
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (NYSE: JNJ).
Jan 22, 2019 08:31 am ET
Option-trading opportunities on Alibaba, IBM, Johnson & Johnson, Tesla, and Under Armour
NEW YORK, Jan. 22, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, IBM, JNJ, TSLA, and UAA....
Jan 22, 2019 05:40 am ET
Johnson & Johnson Reports 2018 Fourth-Quarter Results:
NEW BRUNSWICK, N.J., Jan. 22, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.4 billion for the fourth quarter of 2018, an increase of 1.0% as compared to the fourth quarter of 2017. Operational sales results increased 3.3% and the negative impact of currency was 2.3%. Domestic sales increased 1.5%. International sales increased 0.4%, reflecting operational growth of 5.1% and a negative currency impact of 4.7%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales for the fourth quarter of 2018 increased 5.3%, ...
Jan 18, 2019 09:50 pm ET
JOHNSON & JOHNSON INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Johnson & Johnson - JNJ
NEW ORLEANS, Jan. 18, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Johnson & Johnson ("J&J") (NYSE: JNJ).  ...
Jan 17, 2019 07:30 am ET
Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
NEW BRUNSWICK, N.J., Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new heart health program using an app from Johnson & Johnson in combination with Apple Watch's irregular rhythm notifications and ECG app can accelerate the diagnosis and improve health outcomes of the 33 million people worldwide living with atrial fibrillation (AFib), a condition that can lead to stroke and ot...
Jan 17, 2019 06:00 am ET
Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.
NEW BRUNSWICK, N.J., Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") for a total purchase price of approximately ¥230 billion. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire publicly held shares of the Company for ¥5,900 per share.  Johnson & Johnson plans to acquire the remaining shares of the Company that were not tendered in the tender offer through a share consolidation under Japanese law during the f...
Jan 12, 2019 03:08 pm ET
ATTENTION JNJ EMPLOYEES: Zamansky LLC Investigates Possible ERISA Violations in the Johnson & Johnson Savings Plan
Zamansky LLC investigates Johnson & Johnson Inc. (NYSE:JNJ) (“J&J” or the “Company”) on behalf of its current and former employees for potential violations of the federal Employee Retirement Income Security Act (“ERISA”) in the J&J Savings Plan (the “Plan”). We are investigating whether the ERISA fiduciaries violated duties of prudence by offering J&J stock to employees who are invested in the Plan.
Jan 11, 2019 04:00 pm ET
Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC
NEW BRUNSWICK, N.J., Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) received notice of an unsolicited "mini-tender" offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 shares of common stock of Johnson & Johnson, representing approximately 0.001% of the company's outstanding shares. Peer & Peri's offer price of $98.50 per share in cash is approximately 22.6% lower than the $127.27 closing price of Johnson & Johnson shares on December 28, 2018, the last closing price prior to commencement of the mini-tender offer....
Jan 11, 2019 06:00 am ET
Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd.
NEW BRUNSWICK, N.J., Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") not already held by Johnson & Johnson or its affiliates that was previously announced on October 23, 2018, have been satisfied and the offering period for the tender offer has expired....
Jan 10, 2019 09:24 am ET
Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science
NEW BRUNSWICK, N.J., Jan. 10, 2019 /PRNewswire/ -- Nominations are now being accepted for the 2019 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most dedicated researchers and champions of science whose basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health. Nominations will be accepted until February 28, 2019 at www.pauljanssenaward.com for consideration by an independent selection committee of world-renowned scientists. A $200,000 cash prize will be awarded to the scientist ...
Jan 04, 2019 10:50 pm ET
JOHNSON & JOHNSON INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Johnson & Johnson - JNJ
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (NYSE: JNJ).
Jan 02, 2019 07:55 am ET
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019
NEW BRUNSWICK, N.J., Jan. 2, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2019 of $0.90 per share on the company's common stock. The dividend is payable on March 12, 2019 to shareholders of record at the close of business on February 26, 2019. The ex-dividend date is February 25, 2019....
Dec 28, 2018 04:41 pm ET
ATTENTION JNJ EMPLOYEES: Zamansky LLC Investigates Possible ERISA Violations in the Johnson & Johnson Retirement Savings Plan
Zamansky LLC investigates Johnson & Johnson Inc. (NYSE:JNJ) (“J&J” or the “Company”) on behalf of its current and former employees for potential violations of the federal Employee Retirement Income Security Act (“ERISA”) in the J&J Retirement Savings Plan (the “Plan”). We are investigating the ERISA fiduciaries violated duties of prudence by offering J&J stock to employees who are invested in the Plan.
Dec 24, 2018 07:30 am ET
Johnson & Johnson to Participate in 37th Annual JP Morgan Health Care Conference
NEW BRUNSWICK, N.J., Dec. 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 37th Annual JP Morgan Health Care Conference on Monday, Jan. 7th, at the Westin St. Francis in San Francisco.  Joseph J. Wolk, Executive Vice President and Chief Financial Officer; Jennifer Taubert, Executive Vice President, Pharmaceuticals and Ashley McEvoy, Executive Vice President, Medical Devices, will represent the Company in a session scheduled at 2:30 p.m. (Pacific Time) / 5:30 p.m. (Eastern Time).  Alex Gorsky, Chairman and Chief Executive Officer, will accompany the team for ...
Dec 19, 2018 10:14 am ET
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J., Dec. 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 22nd, to review fourth-quarter results.  Alex Gorsky, Chairman and Chief Executive Officer; Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call.  ...
Dec 18, 2018 08:31 am ET
Option-trading opportunities on American Express Corp., Cisco Systems, Johnson & Johnson, NVIDIA Corp., and Oracle Corp.
NEW YORK, Dec. 18, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXP, CSCO, JNJ, NVDA, and ORCL....
Dec 17, 2018 03:22 pm ET
Johnson & Johnson Announces $5 Billion Share Repurchase Program
NEW BRUNSWICK, N.J., Dec. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock. ...
Dec 17, 2018 08:31 am ET
Thinking about buying stock in Aurora Cannabis Inc, Belmond Ltd, Chesapeake Energy, Diffusion Pharmaceuticals Inc. or Johnson & Johnson?
NEW YORK, Dec. 17, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BEL, CHK, DFFN, and JNJ....
Dec 14, 2018 06:45 pm ET
Bragar Eagel & Squire, P.C. is Investigating Johnson & Johnson (JNJ) on Behalf of Stockholders and Encourages JNJ Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Johnson & Johnson (NYSE: JNJ).  Our investigation concerns whether Johnson & Johnson has violated the federal securities laws and/or engaged in other unlawful business practices....
Dec 14, 2018 04:35 pm ET
NOTICE TO CURRENT AND FORMER EMPLOYEES: Zamansky LLC Investigates the Johnson & Johnson Retirement Savings Plan for Possible ERISA Violations
Zamansky LLC announces that it has commenced an investigation of Johnson & Johnson Inc. (NYSE: JNJ) (“J&J”) on behalf of its current and former employees over the J&J Retirement Savings Plan (the “Plan”) for potential violations of the federal Employee Retirement Income Security Act (“ERISA”). ERISA imposes fiduciary duties to prudently manage and invest plan assets. The firm is investigating whether these duties were violated by the continued offering of J&J stock as an investment option under the Plan.
Dec 14, 2018 04:08 pm ET
Hagens Berman Notifies Johnson & Johnson (JNJ) Investors of the Firm's Investigation of Possible Disclosure Violations
SAN FRANCISCO, Dec. 14, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP notifies investors in Johnson & Johnson (NYSE: JNJ) of the Firm's investigation of possible disclosure violations.  If you purchased or otherwise acquired JNJ shares between May 1, 2018 through December 14, 2018 (the "Class Period") on a U.S. exchange and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:...
Dec 14, 2018 03:06 pm ET
Shareholder Alert: Thornton Law Firm LLP Notifies Shareholders Of Johnson & Johnson (JNJ) Of An Investigation Involving Possible Securities Fraud Related To Disclosure Of Baby Powder/Asbestos In J&J P
BOSTON, Dec. 14, 2018 /PRNewswire/ -- Thornton Law Firm LLP is investigating potential violations of the federal securities laws on behalf of purchasers of the securities of Johnson & Johnson (NYSE ticker: JNJ) regarding recent revelations that J&J knew about asbestos in its baby powder and talcum powder products dating back several decades. Shareholders who purchased or acquired Johnson & Johnson (JNJ) securities, including common stock, may have a claim to recover losses against J&J based on recent revelations concerning asbestos in its baby powder and talcum powder product...
Dec 14, 2018 12:50 pm ET
Statement on Reuters Talc Article
NEW BRUNSWICK, N.J., Dec. 14, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today issued the following statement regarding speculation about the safety of our products. ...
Dec 14, 2018 12:42 pm ET
INVESTOR ALERT: Ademi & O'Reilly, LLP Investigates Whether Johnson & Johnson (JNJ) Violated Securities Laws
MILWAUKEE, Dec. 14, 2018 /PRNewswire/ -- Ademi & O'Reilly, LLP announces an investigation of Johnson & Johnson (NYSE: JNJ) for possible violations of securities laws. ...
Nov 30, 2018 07:20 am ET
Report: Developing Opportunities within Unifirst, Royal Caribbean Cruises, Albemarle, Tableau Software, Huami, and Johnson & Johnson — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Unifirst Corporation (NYSE:UNF), Royal Caribbean Cruises Ltd. (NYSE:RCL),...
Nov 26, 2018 07:00 am ET
Johnson & Johnson to Participate in the BMO Prescriptions for Success Healthcare Conference
NEW BRUNSWICK, N.J., Nov. 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12th, at The Mandarin Oriental, New York.  Ciro Römer, Company Group Chairman for the Johnson & Johnson Medical Devices Companies North America region will represent the Company in a session scheduled at 10:00 a.m. (Eastern). ...
Nov 16, 2018 06:03 am ET
ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'
First-of-its-kind contact lens corrects vision and adapts to changing light conditions ...
Nov 16, 2018 06:03 am ET
ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'
First-of-its-kind contact lens corrects vision and adapts to changing light conditions ...
Nov 12, 2018 07:00 am ET
Johnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference
NEW BRUNSWICK, N.J., Nov. 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi's 2018 Global Healthcare Conference on Wednesday, December 5th, at the Lotte New York Palace Hotel in New York City.  Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 10:15 a.m. (Eastern). ...
Nov 12, 2018 12:30 am ET
Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic
New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition...
Nov 12, 2018 12:30 am ET
Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic
New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition...
Nov 07, 2018 11:36 am ET
Johnson & Johnson Vision Announces Health Canada has issued a Medical Device License for First-of-its-Kind Contact Lens ACUVUE OASYS with Transitions Light Intelligent Technology
Developed in strategic partnership with Transitions Optical, this first-of-its-kind1 contact lens seamlessly adapts to changing light conditions while providing all-day soothing vision2,3...
Nov 06, 2018 09:09 am ET
Johnson & Johnson to Participate in the Credit Suisse 27th Annual Healthcare Conference
NEW BRUNSWICK, N.J., Nov. 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13th, at The Phoenician in Scottsdale, AZ.  Scott White, Company Group Chairman, North America Pharmaceuticals will represent the Company in a session scheduled at 8:35 a.m. (MST). ...
Nov 06, 2018 08:19 am ET
Two Studies Measure Performance of ACUVUE OASYS with Transitions Light Intelligent Technology Contact Lenses in Simulated Sunlight, Day and Night Driving Conditions
JACKSONVILLE, Fla., Nov. 6, 2018 /PRNewswire/ -- Johnson & Johnson Vision today announced that data from two new studies on the visual effects of photochromic contact lenses will be presented at the 2018 American Academy of Optometry Annual Meeting in San Antonio (Academy 2018 San Antonio). Both studies are among the 'most newsworthy' at the meeting, as selected by the American Academy of Optometry. These are the first scientific presentations focused on photochromic contact lens technology since the lenses received 510(k) clearance from the U.S. Food & Drug Administration (FDA) in A...
Oct 26, 2018 05:48 pm ET
Court Issues Ruling in ZYTIGA® Patent Infringement Litigation
NEW BRUNSWICK, N.J., Oct. 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the United States District Court, District of New Jersey has issued a ruling invalidating all asserted claims of U.S. Patent No. 8,822,438 for ZYTIGA® (abiraterone acetate). The Court held that the patent claims would be infringed if the patent were valid. The patent infringement case was filed against several companies who have submitted Abbreviated New Drug Applications for 250 mg and/or 500 mg tablets....
Oct 23, 2018 03:08 am ET
Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd.
NEW BRUNSWICK, N.J., Oct. 23, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company"), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products, to launch an all-cash offer (the "tender offer") to acquire all of the outstanding shares of the Company not already held by Johnson & Johnson and its affiliates for ¥5,900 per share, which equates to approximately ¥230 billion. The acquisition will include the Company's ...
Oct 22, 2018 07:45 am ET
Detailed Research: Economic Perspectives on DexCom, MiX Telematics, Resolute Forest Products, Equinix, Johnson & Johnson, and Vedanta — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DexCom, Inc. (NASDAQ:DXCM), MiX Telematics Limited (NYSE:MIXT), Resolute...
Oct 18, 2018 08:05 am ET
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018
NEW BRUNSWICK, N.J., Oct. 18, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per share on the company's common stock.  The dividend is payable on December 11, 2018 to shareholders of record at the close of business on November 27, 2018. The ex-dividend date is November 26, 2018....
Oct 16, 2018 06:40 am ET
Johnson & Johnson Reports 2018 Third-Quarter Results:
NEW BRUNSWICK, N.J., Oct. 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.3 billion for the third quarter of 2018, an increase of 3.6% as compared to the third quarter of 2017. Operational sales results increased 5.5%, partially offset by the negative impact of currency of 1.9%. Domestic sales increased 3.6%. International sales increased 3.5%, reflecting operational growth of 7.5% and a negative currency impact of 4.0%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.1%, domestic sales in...
Oct 09, 2018 12:00 pm ET
Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced today the appointment of three new members to its Strategic...
Oct 08, 2018 12:00 pm ET
Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Day
JACKSONVILLE, Fla. and SANTA ANA, Calif., Oct. 8, 2018 /PRNewswire/ -- Sight is the most prized of all human senses. Yet, there are many people who do not fully experience the wonder of this gift. Nearly 285 million people around the world face impaired vision, and 80 percent of those cases are preventable with early diagnosis and treatment.1 That's why Johnson & Johnson Vision, a broad-based global leader in eye health, has launched a worldwide campaign to #spotlightsight in honor of World Sight Day on October 11. ...
Oct 02, 2018 12:12 am ET
Platinum Equity Completes $2.1 Billion Acquisition of LifeScan From Johnson & Johnson
Platinum Equity today announced that its acquisition of LifeScan from Johnson Johnson (NYSE: JNJ) for approximately $2.1 billion has been completed, with the exception of certain non-U.S. jurisdictions that are each expected to close at a later...
Oct 02, 2018 12:01 am ET
Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity
NEW BRUNSWICK, N.J., Oct. 2, 2018 /CNW/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 billion. ...
Oct 02, 2018 12:01 am ET
Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity
NEW BRUNSWICK, N.J., Oct. 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 billion. ...
Oct 01, 2018 08:30 am ET
Where will the next big idea in healthcare come from? Johnson & Johnson is counting on nurses.
NEW BRUNSWICK, N.J., Oct. 1, 2018 /PRNewswire/ -- There's a reason the saying goes, "nurse someone back to health." Throughout history, nurses have been important facilitators of health – caring for the sick when others would not, identifying smarter and better ways to heal and developing life-saving methods....
Sep 21, 2018 06:00 pm ET
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
TITUSVILLE, N.J., Sept. 21, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression. Janssen researchers presented these results at the Ninth Biennial Conference of the International Society for Affective Disorders (ISAD) and the Houston Mood Disorders Conference, taking place September 20-22, 2018 in Houston, TX....
Sep 19, 2018 04:57 pm ET
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
NEW BRUNSWICK, N.J., Sept. 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16th, to review third-quarter results.  Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call.  The question and answer portion of the call will also include the following executives: Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices; Jorge Mesquita, Executive Vice President, Worldwide Chairman, Cons...
Sep 04, 2018 08:00 am ET
Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression
TITUSVILLE, N.J., Sept. 4, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for esketamine nasal spray. Janssen is seeking FDA approval of esketamine for treatment-resistant depression in adults....
Aug 27, 2018 02:56 pm ET
UPDATE: Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business
NEW BRUNSWICK, N.J., Aug. 27, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, September 13th, to review its Pharmaceutical Business.  Joaquin Duato, Vice Chairman of the Executive Committee; Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals; Mathai Mammen, Global Head, Janssen Research & Development and Lesley Fishman, Senior Director Investor Relations will host the call....
Aug 27, 2018 09:59 am ET
Johnson & Johnson to Participate in the 2018 Morgan Stanley 16th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J., Aug. 27, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Morgan Stanley 16th Annual Global Healthcare Conference on Friday, September 14th, at The Grand Hyatt Hotel in New York.  Alex Gorsky, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 9:55 a.m. (Eastern Time). ...
Aug 27, 2018 05:32 am ET
Johnson & Johnson to Host Investor Conference Call on the Phase 3 MARINER and COMMANDER HF Studies for XARELTO®
NEW BRUNSWICK, N.J., Aug. 27, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Monday, August 27th, to review the Phase 3 MARINER and COMMANDER HF studies for XARELTO® presented at the European Society of Cardiology Congress 2018.  James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research and Development, LLC.; Vanessa Broadhurst, President, Cardiovascular & Metabolism, Janssen Pharmaceuticals Inc. and Christopher DelOrefice, Vice President, Investor Relations wil...
Aug 23, 2018 11:14 am ET
Caldwell Cassady & Curry Helps Acantha Win $8.2 Million Patent Infringement Verdict Against Medical Device Giant DePuy Synthes
GREEN BAY, Wisc., Aug. 23, 2018 /PRNewswire/ -- The Dallas-based intellectual property and business litigation law firm Caldwell Cassady & Curry has won an $8.2 million patent infringement verdict for Acantha LLC against medical device manufacturer DePuy Synthes, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ)....
Aug 20, 2018 10:19 am ET
Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business
NEW BRUNSWICK, N.J., Aug. 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, September 13th, to review its Pharmaceutical Business.   Joaquin Duato, Vice Chairman of the Executive Committee; Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals; Mathai Mammen, Global Head, Janssen Research & Development and Lesley Fishman, Senior Director Investor Relations will host the call....
Aug 08, 2018 05:30 pm ET
Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations
NEW BRUNSWICK, N.J., Aug. 8, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the appointment of Chris DelOrefice to Vice President of Investor Relations for Johnson & Johnson, effective August 13, 2018. Mr. DelOrefice will report to Mr. Joseph Wolk, Executive Vice President and Chief Financial Officer of the Company.  ...
Aug 07, 2018 02:04 pm ET
Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference
NEW BRUNSWICK, N.J., Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Wells Fargo 13th Annual Healthcare Conference on Thursday, Sept. 6th, at The Westin Boston Waterfront in Boston, MA.  Alex Gorsky, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 9:45 a.m. (Eastern Time).  ...
Aug 07, 2018 01:56 pm ET
Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference
NEW BRUNSWICK, N.J., Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, Sept. 6th, at the InterContinental, Boston, MA.  Jorge Mesquita, Executive Vice President, Worldwide Chairman, Consumer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time). ...
Jul 17, 2018 09:31 am ET
Thinking about buying stock in Advanced Micro Devices, Amazon.com, Helios and Matheson Analytics Inc, Johnson & Johnson or Walmart Stores Inc.?
NEW YORK, July 17, 2018 /PRNewswire/ --  InvestorsObserver issues critical PriceWatch Alerts for AMD, AMZN, HMNY, JNJ, and WMT....
Jul 17, 2018 06:40 am ET
Johnson & Johnson Reports 2018 Second-Quarter Results:
NEW BRUNSWICK, N.J., July 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.8 billion for the second quarter of 2018, an increase of 10.6% as compared to the second quarter of 2017. Operational sales results increased 8.7% and the positive impact of currency was 1.9%. Domestic sales increased 9.4%. International sales increased 11.8%, reflecting operational growth of 7.9% and a positive currency impact of 3.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.3%, domestic sales increa...
Jul 16, 2018 10:47 am ET
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2018
NEW BRUNSWICK, N.J., July 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2018 of $0.90 per share on the company's common stock.  The dividend is payable on September 11, 2018 to shareholders of record at the close of business on August 28, 2018. The ex-dividend date is August 27, 2018....
Jul 12, 2018 07:23 pm ET
St. Louis Jury Returns $4.69 Billion Verdict in First Trial Linking Baby Powder, Asbestos and Ovarian Cancer
ST. LOUIS, July 12, 2018 /PRNewswire/ -- A jury has awarded $4.69 billion to 22 women and their families who alleged that decades of daily use of Johnson & Johnson's (NYSE: JNJ) asbestos-laden talcum powder products caused their ovarian cancer. ...
Jun 26, 2018 08:00 am ET
Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation
TITUSVILLE, N.J., June 26, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson and Johnson & Johnson Innovation LLC are joining with Mental Health America, OneMind, PeaceLove and other leading mental health and arts organizations to leverage the power of artistic creation to break down stigma about mental illnesses and build greater empathy and understanding. Champions of Science: The Art of Ending Stigma, a new global project, encourages all people to share artistic expressions about mental illnesses and the importance of overcoming stigma, while also educ...
Jun 22, 2018 12:31 pm ET
Johnson & Johnson Appoints Senior Leaders to Executive Committee
NEW BRUNSWICK, N.J., June 22, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the appointment of a number of senior leaders to the Company's Executive Committee. ...
Jun 22, 2018 12:30 pm ET
Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson
NEW BRUNSWICK, N.J., June 22, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that Sandra (Sandi) E. Peterson, Group Worldwide Chairman for Johnson & Johnson, has announced her plans to retire from J&J effective October 1, 2018. ...
Jun 19, 2018 10:04 am ET
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J., June 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter results.  Alex Gorsky, Chairman and Chief Executive Officer and Joseph J. Wolk, Executive Vice President, Chief Financial Officer will host the call....
Jun 18, 2018 08:27 am ET
FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio
SANTA ANA, Calif., June 18, 2018 /PRNewswire/ -- Johnson & Johnson Vision announced today the U.S. Food and Drug Administration (FDA) approval of the iDESIGN Refractive Studio, making it the only system to use topography-integrated, wavefront-guided technology.2 This allows doctors to take a precise measurement of the eye inside and out to deliver a LASIK procedure personalized to the individual patient. It is approved for myopia, hyperopia, and mixed astigmatism. Additionally, it is the only available LASIK platform indicated for monovision LASIK in presbyopic myopic patients. Monovisio...
Jun 14, 2018 08:30 pm ET
Kyros Law is Investigating Claims on Behalf of Invokana users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Filed.
BOSTON, June 14, 2018 /PRNewswire/ -- Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking compensation for their injuries. According to a February 22nd filing with the U.S. & Securities and Exchange Commission, Johnson & Johnson (NYSE: JNJ)  and its Janssen Pharmaceuticals unit have been named defendants in approximately 1,100 lawsuits involving Invokana....
Jun 14, 2018 08:00 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Southwestern Energy, Johnson & Johnson, Sleep Number, QUALCOMM, Kirkland's, and Grupo Aval Acciones y Valores S.A — New Research Emp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southwestern Energy Company (NYSE:SWN), Johnson Johnson (NYSE:JNJ),...
Jun 12, 2018 04:01 pm ET
Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
NEW BRUNSWICK, N.J., June 12, 2018 /CNW/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch® brand of products....
Jun 12, 2018 04:01 pm ET
Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
NEW BRUNSWICK, N.J., June 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch® brand of products....
Jun 06, 2018 04:46 pm ET
Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP)
NEW BRUNSWICK, N.J., June 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Fortive Corporation (NYSE: FTV) to acquire its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds from Fortive and $0.1 billion of retained net receivables. ASP is a global leader in innovative infection prevention solutions with 2017 net revenue of approximately $775 million. ...
Jun 05, 2018 08:00 am ET
Johnson & Johnson Announces Progress Toward Health for Humanity Goals
NEW BRUNSWICK, N.J., June 5, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today released its 2017 Health for Humanity Report, demonstrating its approach and the considerable progress it has made toward an ambitious social, environmental and governance commitment to advance the Company's mission to drive better health for all. ...
Jun 04, 2018 09:00 am ET
James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award for Biomedical Research
BOSTON, June 4, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today named James Allison, Ph.D., of University of Texas MD Anderson Cancer Center, winner of the 2018 Dr. Paul Janssen Award for Biomedical Research, and launched several new programs as part of our Champions of Science platform to fuel public engagement, support and trust in science. ...
May 29, 2018 10:53 am ET
Johnson & Johnson to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J., May 29, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, at the Terranea Resort in Rancho Palos Verdes, California.  Tom Cavanaugh, President, Oncology, Janssen Pharmaceuticals and Scott White, President, Immunology will represent the Company in a session scheduled at 9:20 a.m. (Pacific Time). ...
May 24, 2018 03:18 pm ET
California Jury Delivers $25.75 Million Verdict in Asbestos Case Tying Johnson's Baby Powder to Mesothelioma
WEST COVINA, Calif., May 24, 2018 /PRNewswire/ -- A jury in California delivered a $25.75 million verdict against the maker of Johnson's Baby Powder for the deadly asbestos-caused cancer a woman developed after years of using the product....
May 05, 2018 08:00 am ET
New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression
TITUSVILLE, N.J., May 5, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results from two Phase 3 clinical studies of the investigational compound esketamine nasal spray in patients with treatment-resistant depression. These studies will be presented at the American Psychiatric Association Annual Meeting, taking place May 5-9 in New York, NY. ...
May 03, 2018 01:18 pm ET
Johnson & Johnson to Participate in the 2018 UBS Global Health Care Conference
NEW BRUNSWICK, N.J., May 3, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 UBS Global Health Care Conference on Monday, May 21st, at the Grand Hyatt, New York.   Sandi Peterson, Executive Vice President, Group Worldwide Chairman will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). ...
May 02, 2018 12:00 pm ET
Johnson & Johnson to Host Consumer and Medical Devices Business Review
NEW BRUNSWICK, N.J., May 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Consumer and Medical Devices businesses for the investment community beginning with a continental breakfast and access to exhibits at 8:00 a.m. (Eastern Time) on Wednesday, May 16, 2018 at the Hyatt Regency Hotel in New Brunswick, New Jersey, and ending at approximately 2:30 p.m....
Apr 26, 2018 10:26 am ET
Johnson & Johnson Announces Dividend Increase of 7.1%
NEW BRUNSWICK, N.J., April 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per share to $0.90 per share.  The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, N.J....
Apr 24, 2018 04:01 pm ET
Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference
NEW BRUNSWICK, N.J., April 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9th, at The InterContinental Boston.  Mathai Mammen, MD, Ph.D., Global Head, Research & Development, Janssen Research and Development will represent the Company in a session scheduled at 9:20 a.m. (Eastern Time). ...
Apr 17, 2018 09:00 am ET
Stock scores released for Advanced Micro Devices, The Home Depot Inc., Johnson & Johnson, Netflix and United Continental Holdings
CHICAGO, April 17, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, HD, JNJ, NFLX, and UAL....
Apr 17, 2018 07:35 am ET
New Research: Key Drivers of Growth for Johnson & Johnson, Chesapeake Energy, Visa, Celgene, Adobe, and Markel — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Johnson & Johnson (NYSE:JNJ), Chesapeake Energy...
Apr 17, 2018 06:40 am ET
Johnson & Johnson Reports 2018 First-Quarter Results:
NEW BRUNSWICK, N.J., April 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.0 billion for the first quarter of 2018, an increase of 12.6% as compared to the first quarter of 2017. Operational sales results increased 8.4% and the positive impact of currency was 4.2%. Domestic sales increased 6.1%. International sales increased 19.9%, reflecting operational growth of 10.9% and a positive currency impact of 9.0%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.3%, domestic sales increa...
Apr 09, 2018 03:43 pm ET
Glancy Prongay & Murray LLP Reminds Investors of the April 9, 2018 Deadline in the Class Action Lawsuit Against Johnson & Johnson
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 9, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Johnson & Johnson (“J&J” or the “Company”) (NYSE:
Apr 05, 2018 11:00 pm ET
JNJ EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...
Apr 04, 2018 03:00 pm ET
Apr 02, 2018 09:41 pm ET
April 9th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Johnson & Johnson (JNJ)
Law Offices of Howard G. Smith reminds investors of the April 9, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ) securities between February 22, 2013 and February 7, 2018, inclusive (the “Cl
Apr 01, 2018 06:00 am ET
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Johnson & John
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Johnson & Johnson (NYSE: JNJ) (“JNJ” or the “Company”) securities during the period between February 22, 2013 and February 7, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 9, 2018 to seek appointment as lead plaintiff.
Mar 29, 2018 03:21 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Johnson & Johnson Investors (JNJ)
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired securities of Johnson & Johnson (“J&J” or the “Company”) (NYSE: 
Mar 26, 2018 05:25 pm ET
JNJ INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Johnson & Johnson Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired securities of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ) securities between February 22, 2013 and February 7, 2018, inclusive (the “Class Period”). JNJ investors have u
Mar 20, 2018 04:15 pm ET
Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson
NEW BRUNSWICK, N.J., March 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that Dominic J. Caruso, Executive Vice President, Chief Financial Officer, has elected to retire in September 2018 after a distinguished 19-year career with the Company.  Caruso was named CFO in 2007, and served as CFO longer than anyone in the company's 132- year history. ...
Mar 20, 2018 09:24 am ET
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
NEW BRUNSWICK, N.J., March 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 17, to review first-quarter results. Dominic Caruso, Executive Vice President, Chief Financial Officer; Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals and Joseph J. Wolk, Vice President, Investor Relations, will host the call....
Mar 16, 2018 07:33 am ET
Platinum Equity Submits Binding Offer to Acquire LifeScan From Johnson & Johnson
LOS ANGELES, March 16, 2018 (GLOBE NEWSWIRE) -- Platinum Equity announced today that it has submitted a binding offer to acquire LifeScan, Inc. from Johnson & Johnson (NYSE: JNJ) in a transaction valued at approximately $2.1 billion. LifeScan is a...
Mar 16, 2018 07:30 am ET
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
NEW BRUNSWICK, N.J., March 16, 2018 /CNW/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. LifeScan, Inc. is a leader in blood glucose monitoring products with 2017 net revenue of approximately $1.5 billion....
Mar 16, 2018 07:30 am ET
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
NEW BRUNSWICK, N.J., March 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. LifeScan, Inc. is a leader in blood glucose monitoring products with 2017 net revenue of approximately $1.5 billion....
Mar 13, 2018 05:43 pm ET
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Johnson & Johnson Shareholders and a Lead Plaintiff Deadline of April 9, 2018
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Johnson & Johnson (NYSE:JNJ) who purchased shares between February 22, 2013 and February 7, 2018. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws.
Mar 08, 2018 03:32 pm ET
Judge's Order Sets 1,200 Xarelto Product Liability Lawsuits for Separate Jury Trials
NEW ORLEANS, March 8, 2018 /PRNewswire/ -- A federal district judge in New Orleans has ordered that 1,200 product defect lawsuits against leading prescription painkiller Xarelto be prepared for trial in federal courts across the country....
Mar 08, 2018 03:11 pm ET
JNJ EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) securities between February 22, 2013 and February 7, 2018.
Mar 07, 2018 03:55 pm ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson (NYSE: JNJ) To Contact Brower Piven Before The Lead Plaintiff Deadline I
STEVENSON, Md., March 07, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of...
Mar 07, 2018 10:00 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline: April 9, 2018
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Johnson & Johnson (“J&J” or the “Company”) (NYSE:JNJ) and certain of...
Mar 06, 2018 01:52 pm ET
Johnson & Johnson to Participate in Barclays Global Healthcare Conference
NEW BRUNSWICK, N.J., March 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Tuesday, Mar. 13, at the Loews Miami Beach Hotel, Miami, FL.  Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). ...
Mar 05, 2018 03:50 pm ET
The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Johnson & Johnson Shareholders and a Lead Plaintiff Deadline of April 9, 2018
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Johnson & Johnson (NYSE:JNJ) who purchased shares between February 22, 2013 and February 7, 2018. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws.
Mar 05, 2018 01:02 pm ET
EQUITY NOTICE: Rosen Law Firm Files Securities Class Action Lawsuit Against Johnson & Johnson – JNJ
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Johnson & Johnson (NYSE:JNJ) between...
Feb 28, 2018 11:18 am ET
The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Johnson & Johnson Shareholders and a Lead Plaintiff Deadline of April 9, 2018
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Johnson & Johnson (NYSE: JNJ) who purchased shares between February 22, 2013 and February 7, 2018. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws.
Feb 27, 2018 03:55 pm ET
The Klein Law Firm Announces a Class Action Filed on Behalf of Johnson & Johnson Shareholders and a Lead Plaintiff Deadline of April 9, 2018 (JNJ)
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Johnson & Johnson (NYSE:JNJ) who purchased shares between February 22, 2013 and...
Feb 27, 2018 12:57 pm ET
JNJ INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Johnson & Johnson
The law firm Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the publicly trade
Feb 23, 2018 02:37 pm ET
JNJ INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Johnson & Johnson ("Johnson & Johnson") (NYSE: JNJ) securities between February 22, 2013 and February 7, 2018.
Feb 22, 2018 02:15 pm ET
JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018
NEW YORK, Feb. 22, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...
Feb 22, 2018 01:33 pm ET
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Acti
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Johnson & Johnson (NYSE: JNJ) (“JNJ” or the “Company”) securities during the period between February 22, 2013 and February 7, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 9, 2018 to seek appointment as lead plaintiff.
Feb 20, 2018 03:43 pm ET
Johnson & Johnson to Participate in Cowen 38th Annual Healthcare Conference
NEW BRUNSWICK, N.J., Feb. 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 38th Annual Healthcare Conference on Tuesday, Mar. 13, at The Boston Marriott Copley Place, Boston. Ashley McEvoy, Company Group Chairman, Consumer Medical Devices will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). ...
Feb 20, 2018 03:19 pm ET
JNJ INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Johnson & Johnson Investors
Law Offices of Howard G. Smith continues its investigation on behalf of Johnson & Johnson Investors (“J&J” or the “Company”) (NYSE: JNJ) investors concerning the Company and its officers’ possible violations of federal securities laws.
Feb 20, 2018 02:18 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Johnson & Johnson of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 – JNJ
NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
Feb 20, 2018 10:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline - April 9, 2018
NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Johnson & Johnson (“J&J” or the “Company”) (NYSE:JNJ) and certain of...
Feb 16, 2018 01:15 pm ET
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & Johnson
The Klein Law Firm announces the commencement of an investigation of Johnson & Johnson (NYSE: JNJ) concerning possible violations of federal securities laws.
Feb 16, 2018 09:03 am ET
Johnson & Johnson Consumer Presents New Scientific Research At 2018 American Academy of Dermatology Annual Meeting
SKILLMAN, N.J., Feb. 16, 2018 /PRNewswire/ -- Reinforcing leadership in scientifically-driven skincare, Johnson & Johnson Consumer Inc. will present eight Scientific Posters at this year's American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA.  The new research spans priority areas across skin health, including photoprotection, acne, cleansing and microbiome....
Feb 15, 2018 04:38 pm ET
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Johnson & Johnson Investors (JNJ)
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Johnson & Johnson (“J&J” or the “Company”) (NYSE: 
Feb 15, 2018 01:53 pm ET
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & Johnson
The Klein Law Firm announces the commencement of an investigation of Johnson & Johnson (NYSE: JNJ) concerning possible violations of federal securities laws.
Feb 14, 2018 03:07 pm ET
Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of a Securities Class Action Against Johnson & Johnson (JNJ)
Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Johnson & Johnson (NYSE: JNJ) (“J&J” or the “Company”) and other defendants, related to alleged v
Feb 14, 2018 02:45 pm ET
JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Johnson & Johnson (“Johnson & Johnson” or the “Company”) (NYSE: JNJ) violated federal securities laws.
Feb 13, 2018 12:25 pm ET
JNJ LOSS NOTICE: Rosen Law Firm Reminds Johnson & Johnson Investors of Important Deadline in First Filed Case
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Johnson & Johnson (NYSE: JNJ) between February 22, 2013 and February 7, 2018, both dates inclusive (“Class Period”) of the important April 9, 2018 lead plaintiff deadline in the first-filed class action commenced by the Rosen Law Firm. The lawsuit seeks to recover damages for J&J investors under the federal securities laws.
Feb 13, 2018 11:44 am ET
JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Johnson & Johnson (“Johnson & Johnson” or the “Company”) (NYSE: JNJ) violated federal securities laws.
Feb 12, 2018 07:30 pm ET
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson (NYSE: JNJ) To Contact Brower
STEVENSON, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of...
Feb 12, 2018 02:37 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson -- JNJ
Levi & Korsinsky announces it has commenced an investigation of Johnson & Johnson (NYSE:JNJ) (“Johnson & Johnson” or the “Company”) concerning possible violations of federal securities laws.
Feb 09, 2018 08:32 pm ET
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Johnson & Johnson Investors (JNJ)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Johnson & Johnson (“J&J” or the “Company”) (NYSE: 
Feb 09, 2018 02:48 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson
Levi & Korsinsky announces it has commenced an investigation of Johnson & Johnson (NYSE:JNJ) (“Johnson & Johnson” or the “Company”) concerning possible violations of federal securities laws.
Feb 09, 2018 11:02 am ET
Rosen Law Firm Files Securities Class Action Lawsuit Against Johnson & Johnson
Rosen Law Firm, a global investor rights law firm, today announced it has filed a federal securities class action lawsuit on behalf of purchasers of the securities of Johnson & Johnson (NYSE:JNJ) between Feb. 22, 2013, and Feb. 7, 2018, both dates inclusive (“Class Period.”) The lawsuit seeks to recover damages for J&J investors under the federal securities laws.
Feb 09, 2018 09:30 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline: April 9, 2018
NEW YORK, Feb. 9, 2018 /CNW/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ) and certain of its officers, on behalf of shareholders who purchased J&J securities during the period between February 22, 2013 and February 7, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/jnj. ...
Feb 09, 2018 09:30 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline: April 9, 2018
NEW YORK, Feb. 9, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ) and certain of its officers, on behalf of shareholders who purchased J&J securities during the period between February 22, 2013 and February 7, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/jnj. ...
Feb 08, 2018 08:54 pm ET
JNJ INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Johnson & Johnson Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Johnson & Johnson Investors (“J&J” or the “Company”) (NYSE: JNJ) investors concerning the Company and its officers’ possible violations of federal securities laws.
Feb 08, 2018 10:41 am ET
Johnson & Johnson to Participate in the 2018 CAGNY Conference
NEW BRUNSWICK, N.J., Feb. 8, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 CAGNY Conference on Thursday, Feb. 22, at The Boca Raton Resort, Boca Raton, FL.  Jorge Mesquita, Executive Vice President, Worldwide Chairman, Consumer and Alison Lewis, Chief Marketing Officer, Consumer will represent the Company in a session scheduled at 2:00 p.m. (Eastern Time). ...
Feb 08, 2018 09:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Johnson & Johnson (JNJ)
NEW YORK, Feb. 8, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/jnj. ...
Feb 08, 2018 07:30 am ET
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
NEW BRUNSWICK, N.J., Feb. 8, 2018 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN data for the investigational compound apalutamide in non-metastatic castration-resistant prostate cancer. The webcast is intended for investors and other interested parties, and will be available beginning at 5:00p.m EST on Thursday, February 8, 2018....
Feb 07, 2018 06:30 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Johnson & Johnson – JNJ
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of Johnson & Johnson (NYSE:JNJ) resulting from...
Feb 07, 2018 09:58 am ET
Johnson & Johnson to Participate in RBC Capital Markets 2018 Global Healthcare Conference
NEW BRUNSWICK, N.J., Feb. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, Feb. 21, at the Lotte New York Palace in New York City.  Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 1:30 p.m. (Eastern Time). ...
Feb 01, 2018 08:00 am ET
Market Trends Toward New Normal in Alexander's, Atrion, FS, Gilead Sciences, Abbott Laboratories, and Johnson & Johnson — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alexander's, Inc. (NYSE:ALX), Atrion Corporation (NASDAQ:ATRI),...
Jan 31, 2018 01:18 pm ET
Johnson & Johnson to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J., Jan. 31, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, Feb. 14, at Lotte New York Palace, NY.  Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 9:30 a.m. (Eastern Time). ...
Jan 23, 2018 08:31 am ET
Investing in Amazon.com, Alibaba, Johnson & Johnson, Tesla Motors or Verizon Communications?
CHICAGO, Jan. 23, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, BABA, JNJ, TSLA, and VZ....
Jan 23, 2018 05:40 am ET
Johnson & Johnson Reports 2017 Fourth-Quarter Results:
NEW BRUNSWICK, N.J., Jan. 23, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.2 billion for the fourth quarter of 2017, an increase of 11.5% as compared to the fourth quarter of 2016. Operational sales results increased 9.4% and the positive impact of currency was 2.1%. Domestic sales increased 9.8%. International sales increased 13.5%, reflecting operational growth of 9.0% and a positive currency impact of 4.5%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales for the fourth quarter of 2017 increased 4.2%...
Jan 17, 2018 04:02 pm ET
Johnson & Johnson Issues Statement on ZYTIGA® Inter Partes Reviews
NEW BRUNSWICK, N.J., Jan. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate):...
Jan 03, 2018 02:00 pm ET
Dr. Paul Janssen Award for Biomedical Research Issues 2018 Call for Nominations to Celebrate Champions of Science
NEW BRUNSWICK, N.J., Jan. 3, 2018 /PRNewswire/ -- Nominations are now being accepted for the 2018 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most dedicated researchers and champions of science whose basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health. Nominations will be accepted until February 28, 2018 at www.pauljanssenaward.com for consideration by an independent selection committee of world-renowned scientists. A $200,000 cash prize will be awarded to the scientist o...
Jan 02, 2018 05:45 am ET
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2018
NEW BRUNSWICK, N.J., Jan. 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2018 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders of record at the close of business on February 27, 2018. The ex-dividend date is February 26, 2018....
Dec 19, 2017 07:30 am ET
Johnson & Johnson to Participate in 36th Annual JP Morgan Health Care Conference
NEW BRUNSWICK, N.J., Dec. 19, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 36th Annual JP Morgan Health Care Conference on Monday, Jan. 8, at the Westin St. Francis in San Francisco.  Alex Gorsky, Chairman and Chief Executive Officer, will represent the Company in a session scheduled at 2:30 p.m. (Pacific Time)/5:30 p.m. (Eastern Time).  A subsequent Question & Answer session is scheduled for 3:00 p.m. (Pacific Time)/6:00 p.m. (Eastern Time)....
Dec 19, 2017 07:20 am ET
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J., Dec. 19, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23rd, to review fourth-quarter results.  Alex Gorsky, Chairman and Chief Executive Officer; Dominic Caruso, Executive Vice President, Chief Financial Officer and Joseph J. Wolk, Vice President, Investor Relations, will host the call....
Dec 12, 2017 08:00 am ET
Motus GI Appoints Gary J. Pruden, Former Worldwide Chairman for Johnson & Johnson Medical Devices Group, to its Board of Directors
Motus GI Holdings, Inc., ("Motus" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has appointed Gary J. Pruden to its Board of Directors. Mr. Pruden most recently...
Nov 30, 2017 02:34 pm ET
Johnson & Johnson to Participate in the BMO Capital Markets Healthcare Conference
NEW BRUNSWICK, N.J., Nov. 30, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the BMO Capital Markets Healthcare Conference on Thursday, Dec. 14, at the Westin Grand Central, in New York, NY.  Sandi Peterson, Executive Vice President, Group Worldwide Chairman will represent the Company in a session scheduled at 8:30 a.m. (Eastern Time). ...
Nov 30, 2017 09:44 am ET
Missouri Judge Upholds $110 Million Talc Verdict
ST. LOUIS, Nov. 30, 2017 /PRNewswire/ -- A Missouri judge has upheld the $110 million jury award to a Virginia woman who claimed that decades of daily use of Johnson & Johnson's (NYSE: JNJ) talcum powder products caused her ovarian cancer....
Nov 28, 2017 07:40 am ET
Research Report Identifies Allergan, Johnson & Johnson, Ford Motor, CSX, Gamestop, and L Brands with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 28, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allergan PLC. (NYSE:AGN), Johnson & Johnson...
Nov 20, 2017 12:47 pm ET
Johnson & Johnson to Participate in the Citi 2017 Global Healthcare Conference
NEW BRUNSWICK, N.J., Nov. 20, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi 2017 Global Healthcare Conference on Thursday, Dec. 7, at Lotte New York Palace, NY.  Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 12:35 p.m. (Eastern Time). ...
Nov 16, 2017 02:23 pm ET
Federal Jury Returns $247 Million Verdict in Defective Hip Implants Case
DALLAS, Nov. 16, 2017 /PRNewswire/ -- A federal court jury in Texas returned a $247 million verdict on behalf of six people who suffered serious medical complications caused by the defective metal-on-metal hip implants made by Johnson & Johnson (NYSE: JNJ) and its subsidiary DePuy Orthopaedics Inc....
Nov 13, 2017 08:04 am ET
Johnson & Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Toughest Consumer Skincare Problems
SAN FRANCISCO, Nov. 13, 2017 /CNW/ -- Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., today announced the launch of the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital beauty solutions in an effort to provide better skincare outcomes for consumers around the world. The winner(s) of the challenge will receive up to a total of $50,000 in funding to help advance their product prototype toward commercialization. In addition to funding, Johnson & Johnson Innova...